Pepper Bio’s Post

IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer

Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses https://lnkd.in/gpfYYvx4  

Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses https://lnkd.in/gpfYYvx4  

Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses https://lnkd.in/gpfYYvx4  

Black Diamond is developing oral therapeutics for patients with #NSCLC and #GBM. CEO Mark Velleca recently spoke with PharmaVoice about Black Diamond’s vision and clinical programs. Read more in this Biotech Spotlight below, and find us at the American Association for Cancer Research Annual Meeting on April 7 where Etienne Dardenne will be presenting real world data of the evolving #EGFR mutation landscape in #NSCLC, and the first- and best-in-class profile of BDTX-1535. #AACR2024

A consortium of pancreatic cancer researchers is sharing informations that has shown that an oral inhibitor, effectively targets the common cancer-causing RAS proteins while minimally impacting normal cells. In this article we will know about this discovery that holds the promise of improving the prognosis for patients with PDAC and potentially other cancers with RAS mutations, marking a hopeful step forward in oncology. https://lnkd.in/dutEEDNt #pancreaticcancer, #clincaltrials

At #ASCO24, a presentation on advancements in the treatment of lung cancer provides a helpful overview of updates in FDA approvals and treatment strategies for metastatic non–small cell lung cancer (NSCLC) since ASCO 2023. Matthew A. Gubens, MD, MS, FASCO, highlights the importance of identifying genetic targets in NSCLC, noting his mantra "You can't treat a target you haven’t identified." https://lnkd.in/eGQHqrgU

Lantern Pharma's expansion of its Phase II Harmonic trial into Japan and Taiwan marks a pivotal step in lung cancer treatment for never-smokers. This trial assesses the efficacy of LP-300 combined with chemotherapy, focusing on non-small cell lung cancer (NSCLC). Key Points: ▪️ Targeted Treatment - Investigating LP-300 in populations with high rates of specific genetic mutations. ▪️ Global Impact - Aiming to gather vital data quickly to push forward LP-300's development. Considerations: ▪️ How will this trial influence global approaches to cancer treatment? ▪️ What strategies should be adopted to meet the needs of diverse patient populations? #CancerResearch #ClinicalTrials #PersonalizedMedicine

Apollomics presented vebreltinib data at the 2024 AACR meeting. Preclinical studies demonstrate vebreltinib is effective for a variety of tumor types carrying MET-driver alterations, and effective for overcoming MET-amplification dependent resistance to EGFR therapies in EGFR-positive non-small cell lung cancer. Vebreltinib is a potent, small molecule, orally bioavailable, brain penetrating and highly selective c-MET inhibitor. It works by inhibiting the aberrant activation of the HGF/MET axis, a key pathway involved in tumor growth, proliferation, and the development of resistance to certain targeted therapies such as osimertinib. By targeting MET dysregulation, vebreltinib offers a potential breakthrough for many cancers driven by MET alterations. #QMportolio #QMhealthcare #cancertreatment #AACR #apollomics #clinicalstudy https://lnkd.in/gCsyHXaP

A novel organoid-on-a-chip model for evaluating emerging cancer immuno-therapeutics. #organoidonchip #cancer #immunotherpeutics #cancerimmunotherapy #antibodydrugs #TBS #3dorganengineering #biomedicalengineering #102capital #medtech #biotech #3dprinting #tissueengineering #kidneydisease #cellbiology